Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viralym-A for Adenovirus Infections Post-HSCT
NCT02276820Phase 1Withdrawn
- Sponsor
- AlloVir
- Start
- Dec 2017
- Primary completion
- Dec 2018
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Viralym-A in adenovirus infection, sponsored by AlloVir. Primary endpoint: Assessment of patients with adverse events after Viralym-A infusion at 42 days. Planned start Dec 2017; status: withdrawn.
02
Drugs
Viralym-A
03
Conditions
adenovirus infection
Beyond the preview
Go deeper on NCT02276820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02276820.